Pluribus Labs’s Fulgent Genetics FLGT Stock Holding History

Pluribus Labs’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,438	Closed	-$346K	–	119
2021 Q4	$346K	Buy	+3,438	New	+$302K	0.36%	108

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Pluribus Labs's FLGT Position: Q1 2022 in Review

Pluribus Labs sold out of Fulgent Genetics (FLGT) in Q1 2022, closing a stake of 3,438 shares — an estimated $346K sold.

Pluribus Labs first reported a position in FLGT in Q4 2021 and held it in 1 quarter. The position peaked at $346K in Q4 2021. 275 funds tracked by Wall St. Rank hold FLGT as of Q1 2022.

Pluribus Labs reported no remaining Fulgent Genetics position as of Q1 2022 after selling out during the quarter.
Pluribus Labs sold 3,438 Fulgent Genetics shares in Q1 2022, an estimated $346K.
Pluribus Labs first reported a position in Fulgent Genetics in Q4 2021 and held it in 1 quarter.
Pluribus Labs's Fulgent Genetics position peaked at $346K in Q4 2021.
275 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2022.

Based on Pluribus Labs's 13F filing for Q1 2022, filed 16 May 2022.